Cephalexin twice daily versus four times daily for the treatment of urinary tract infections diagnosed in the emergency department

IF 2.7 3区医学 Q1 EMERGENCY MEDICINE

American Journal of Emergency Medicine Pub Date : 2025-03-24 DOI:10.1016/j.ajem.2025.03.058

Abigail Rath PharmD , Taylor Morrisette PharmD, MPH , Aaron Hamby PharmD, BCIDP , Rachel Burgoon PharmD, BCIDP , Kelsey Billups PharmD, BCPS, BCEMP

{"title":"Cephalexin twice daily versus four times daily for the treatment of urinary tract infections diagnosed in the emergency department","authors":"Abigail Rath PharmD , Taylor Morrisette PharmD, MPH , Aaron Hamby PharmD, BCIDP , Rachel Burgoon PharmD, BCIDP , Kelsey Billups PharmD, BCPS, BCEMP","doi":"10.1016/j.ajem.2025.03.058","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cephalexin is an oral cephalosporin approved for the treatment of urinary tract infections (UTIs). Data regarding the optimal dosing interval for cephalexin in UTIs, including uncomplicated UTIs (uUTI) and complicated UTIs (cUTI), remains limited.</div></div><div><h3>Objective</h3><div>The primary objective of this study was to compare the rates of treatment failure between patients prescribed cephalexin twice daily versus four times daily for the management of uUTIs and cUTIs once discharged from the emergency department (ED).</div></div><div><h3>Methods</h3><div>This retrospective, single-center cohort study conducted between July 31st, 2016 and July 31st, 2023, included patients who were ≥ 18 years of age, discharged from the ED with a diagnosis of UTI, prescribed cephalexin 500 mg twice or four time daily, and a urine culture positive for <em>Escherichia coli, Klebsiella pneumoniae,</em> or <em>Proteus mirabilis</em> susceptible to cefazolin. Treatment failure was defined as return to the ED or outpatient clinic with similar or worsening UTI symptoms or change in antibiotic therapy within 30 days of the initial ED visit. Sub-group analyses were performed for both uUTI and cUTIs.</div></div><div><h3>Results</h3><div>In total, 214 patients were included in this analysis (50.0 % in each group). Treatment failure rates between the twice daily and four times daily dosing groups were 18.7 % versus 15.0 % (<em>P</em> = 0.465). Treatment failure rates in those with uUTI were 14.9 % versus 8.1 % (<em>P</em> = 0.197) and those with cUTI were 27.3 % versus 30.3 % (<em>P</em> = 0.786).</div></div><div><h3>Conclusion</h3><div>For patients with UTIs, there was no statistically significant difference in treatment failure rates between patients prescribed cephalexin twice daily versus four times daily. These findings suggest cephalexin dosed twice daily may be a reasonable option for the outpatient management of UTIs diagnosed in the ED, thus increasing adherence and decreasing cost without statistically compromising effectiveness.</div></div>","PeriodicalId":55536,"journal":{"name":"American Journal of Emergency Medicine","volume":"93 ","pages":"Pages 80-85"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Emergency Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0735675725002232","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cephalexin is an oral cephalosporin approved for the treatment of urinary tract infections (UTIs). Data regarding the optimal dosing interval for cephalexin in UTIs, including uncomplicated UTIs (uUTI) and complicated UTIs (cUTI), remains limited.

Objective

The primary objective of this study was to compare the rates of treatment failure between patients prescribed cephalexin twice daily versus four times daily for the management of uUTIs and cUTIs once discharged from the emergency department (ED).

Methods

This retrospective, single-center cohort study conducted between July 31st, 2016 and July 31st, 2023, included patients who were ≥ 18 years of age, discharged from the ED with a diagnosis of UTI, prescribed cephalexin 500 mg twice or four time daily, and a urine culture positive for Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis susceptible to cefazolin. Treatment failure was defined as return to the ED or outpatient clinic with similar or worsening UTI symptoms or change in antibiotic therapy within 30 days of the initial ED visit. Sub-group analyses were performed for both uUTI and cUTIs.

Results

In total, 214 patients were included in this analysis (50.0 % in each group). Treatment failure rates between the twice daily and four times daily dosing groups were 18.7 % versus 15.0 % (P = 0.465). Treatment failure rates in those with uUTI were 14.9 % versus 8.1 % (P = 0.197) and those with cUTI were 27.3 % versus 30.3 % (P = 0.786).

Conclusion

For patients with UTIs, there was no statistically significant difference in treatment failure rates between patients prescribed cephalexin twice daily versus four times daily. These findings suggest cephalexin dosed twice daily may be a reasonable option for the outpatient management of UTIs diagnosed in the ED, thus increasing adherence and decreasing cost without statistically compromising effectiveness.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Emergency Medicine 医学-急救医学

CiteScore

6.00

自引率

5.60%

发文量

730

审稿时长

42 days

期刊介绍： A distinctive blend of practicality and scholarliness makes the American Journal of Emergency Medicine a key source for information on emergency medical care. Covering all activities concerned with emergency medicine, it is the journal to turn to for information to help increase the ability to understand, recognize and treat emergency conditions. Issues contain clinical articles, case reports, review articles, editorials, international notes, book reviews and more.